跳至主要内容
临床试验/NCT05903963
NCT05903963招募中1 期

Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit

Minia University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年5月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
40
试验地点
1
主要终点
Incidence of acute kidney injury

研究概览

简要总结

Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age (18-80) years old. sex:both male and female.
  • intubated and mechanically ventilated patients.

排除标准

  • 1.Patient's relatives refusal.
  • burns as admitting diagnoses. 3.patients with any renal pathology(such as chronic glomerulonephritis, pyelonephritis and diabetic nephropathy).
  • pregnancy or lactation.
  • serious central nervous system pathology (acute stroke, uncontrolled seizures, severe dementia).
  • acute hepatitis or severe liver disease (Child-Pugh class C).
  • unstable angina or acute myocardial infarction, left ventricular ejection fraction less than 30%, heart rate less than 50/min, second- or third-degree heart block, or systolic blood pressure less than 90 mm Hg despite continuous infusions of 2 vasopressors before the start of study drug infusion.

研究组 & 干预措施

Midazolam group

Active Comparator

干预措施: Midazolam (Drug)

dexmedetomidine group

Active Comparator

干预措施: dexmedetomidine (Drug)

结局指标

主要结局

Incidence of acute kidney injury

时间窗: 5 days

urinary kidney injury molecule

次要结局

  • length of ICU stay(10 days)

研究者

发起方
Minia University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Marlin Zarif Shehata Yousef

Ass. lecturer of anesthesia and pain medicine

Minia University

研究点 (1)

Loading locations...

相似试验